Oxurion Receives Transparency Notifications from Negma Group
21 February 2023 - 03:00AM
Oxurion Receives Transparency Notifications from Negma Group
Oxurion Receives
Transparency Notifications from
Negma Group
Leuven, BELGIUM, Boston, MA, US
– February
17, 2022 –
7.00
PM CET Oxurion NV (Euronext
Brussels: OXUR) a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, with clinical
stage assets in vascular retinal disorders, today announced that,
pursuant to Belgian Transparency legislation1 it has received a
transparency notification as follows:
Oxurion received a transparency notification on
February 14, 2023 from Negma Group Ltd. indicating that as of
February 9, 2023, it held no shares of the then outstanding
493,468,012 shares, and therefore crossed below the threshold (3%)
by virtue of disposal of voting securities. See Annex 1
Oxurion received a transparency notification on
February 13, 2023 from Negma Group Ltd. indicating that as of
February 8, 2023, it held 15,503,696 shares of the then
outstanding 493,468,012 shares, and therefore crossed above the
threshold (3%) by virtue of acquisition of voting securities. See
Annex 2
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10
" tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.com
ICR WestwickeChristopher BrinzeyTel: +1 617 835
9304Chris.Brinzey@westwicke.com |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on
disclosure of major holdings.
ANNEX 1
ANNEX 2
- OXUR Transparency Notification (EN) 2023.2.17.FINAL2
- OXUR Transparency Notification (NL) 2023.2.17.FINAL
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Mar 2023 to Mar 2024